Halozyme Therapeutics, Inc. (BIT:1HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 13, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	6,507	7,927	5,887	4,685	7,690	5,529
Market Cap Growth	-4.13%	34.64%	25.65%	-39.07%	39.09%	-4.70%
Enterprise Value	8,272	9,927	6,797	5,849	8,820	5,575
PE Ratio	24.11	26.29	13.94	17.60	39.51	14.68
Forward PE	7.83	8.85	10.38	9.77	21.92	17.89
PEG Ratio	-	0.41	0.41	0.41	0.41	0.46
PS Ratio	5.47	5.68	5.80	5.65	11.65	12.47
PB Ratio	156.52	162.39	16.18	55.91	45.29	28.07
P/TBV Ratio	151.38	170.83	17.01	59.18	47.12	29.97
P/FCF Ratio	11.85	12.30	12.57	12.55	32.68	18.55
P/OCF Ratio	11.73	12.17	12.29	12.06	32.03	18.46
EV/Sales Ratio	6.83	7.11	6.69	7.05	13.36	12.58
EV/EBITDA Ratio	10.51	17.82	10.74	13.85	27.81	19.99
EV/EBIT Ratio	11.68	21.17	12.33	17.33	32.97	20.21
EV/FCF Ratio	15.07	15.40	14.51	15.67	37.49	18.71
Debt / Equity Ratio	43.89	43.89	4.14	17.89	8.79	4.00
Debt / EBITDA Ratio	3.85	3.85	2.38	3.55	4.75	3.14
Debt / FCF Ratio	3.32	3.32	3.22	4.02	6.40	2.94
Net Debt / Equity Ratio	40.97	40.97	2.50	13.88	6.73	0.69
Net Debt / EBITDA Ratio	3.59	3.59	1.44	2.75	3.61	0.49
Net Debt / FCF Ratio	3.10	3.10	1.94	3.12	4.86	0.46
Asset Turnover	0.61	0.61	0.53	0.46	0.45	0.53
Inventory Turnover	1.44	1.44	1.18	1.69	1.81	1.42
Quick Ratio	3.30	3.30	6.50	5.07	4.54	7.10
Current Ratio	4.66	4.66	7.80	6.64	5.65	7.91
Return on Equity (ROE)	153.59%	153.59%	198.42%	222.07%	110.23%	231.44%
Return on Assets (ROA)	13.87%	13.87%	23.16%	15.27%	14.75%	53.09%
Return on Invested Capital (ROIC)	18.02%	18.02%	33.64%	20.63%	25.58%	169.66%
Return on Capital Employed (ROCE)	21.95%	21.95%	31.11%	20.27%	19.83%	48.16%
Earnings Yield	4.15%	3.80%	7.17%	5.68%	2.53%	6.81%
FCF Yield	8.44%	8.13%	7.96%	7.97%	3.06%	5.39%
Buyback Yield / Dilution	4.09%	4.04%	3.72%	8.21%	2.42%	6.10%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.